Through this preclinical study, we provide evidences for the use of irreversible TKIs as a novel approach to reduce tumor burden as well as incidence of metastasis by down regulating MUC4 in advanced pancreatic cancer patients. Here, MUC4 is linked to pancreatic neoplasm.